Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Pharmacokinetics of Sustained-release Depot Tacrolimus: A First-in-human Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03626714
Recruitment Status : Completed
First Posted : August 13, 2018
Results First Posted : June 11, 2019
Last Update Posted : August 13, 2019
Sponsor:
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by (Responsible Party):
Auritec Pharmaceuticals

Brief Summary:
This first-in-human study is designed to assess the safety and pharmacokinetic (PK) profile of sustained-release (SR) depot tacrolimus, which will be administered as a single dose of 0.1 mg/kg by subcutaneous (SC) injection in healthy subjects.

Condition or disease Intervention/treatment Phase
Organ Transplant Rejection Psoriasis Drug: Sustained Release Injectable Tacrolimus Early Phase 1

Detailed Description:

This is a first-in-human study to assess the safety and pharmacokinetic (PK) profile of sustained-release (SR) tacrolimus, which will be administered as a single dose of 0.1 mg/kg by subcutaneous (SC) injection in healthy subjects.

The short-term general investigational plan is to evaluate sustained release tacrolimus in healthy volunteers for up to 30 days in an exploratory trial to determine safety and drug concentrations in blood. The results from this study will inform the long-term goal of this program, which is to provide an improved treatment modality for prophylaxis of organ (kidney, liver and heart) transplant rejection with the additional benefit of enhancing medication compliance. These improvements have the potential to mitigate both the personal and economic burden of this disease.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 8 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, First-in-human, Safety and Pharmacokinetic Study of 1-Month Sustained-Release Injectable Tacrolimus in Healthy Subjects
Actual Study Start Date : October 16, 2018
Actual Primary Completion Date : January 5, 2019
Actual Study Completion Date : January 5, 2019

Resource links provided by the National Library of Medicine

Drug Information available for: Tacrolimus

Arm Intervention/treatment
Experimental: Sustained Release Tacrolimus
All subjects will be treated with a single dose injection of sustained-release Tacrolimus
Drug: Sustained Release Injectable Tacrolimus
Long-acting formulation of tacrolimus developed using Auritec's proprietary Plexis drug delivery technology.




Primary Outcome Measures :
  1. Number of Subjects That Experienced Treatment-related Adverse Events [Safety and Tolerability] [ Time Frame: 60 days ]

    Adverse events were documented at each study visit according to the criteria set forth in the Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials as follows:

    Grade 1 (mild); Grade 2 (moderate); Grade 3 (severe); Grade 4 (potentially life-threatening).


  2. Drug Concentrations in Blood Samples at Individual Time-points [ Time Frame: 60 days ]
    The concentrations of tacrolimus in blood samples were measured at baseline, day 1 (1 hr, 3 hrs, 6 hrs, 12 hrs, and 24 hrs), followed by days 3, 7, 14, 21, 30, 37, 44, 51 and 60.

  3. Mean Blood Concentration-time Curve - Cmax [ Time Frame: 60 days ]
    Maximum observed tacrolimus whole blood concentration

  4. Mean Blood Concentration-time Curve - Tmax [ Time Frame: 60 days ]
    Time to maximum observed tacrolimus whole blood concentration

  5. Blood Concentration-time Curve [AUC] [ Time Frame: 60 days ]
    Area under the concentration-time curve

  6. Terminal Elimination Half-life [t1/2] [ Time Frame: 60 days ]
    The apparent terminal elimination half-life was calculated.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Subjects must be able to understand and provide informed consent. A signed informed consent form must be provided before any study assessments are done;
  • Males or females, between 18 and 45 years of age, inclusive;
  • Body mass index must be within the range 18.5 to 32.0 kg/m2, inclusive;
  • Must be in good health, as determined by no clinically significant findings from medical history, vital signs, and 12-lead electrocardiogram (ECG), inclusive of documented absence of QT prolongation;
  • Clinical laboratory evaluations (including clinical chemistry panel [fasted at least 10 hours], complete blood count [CBC], and urinalysis [UA]) must be within the reference range for the test laboratory, unless deemed not clinically significant by the Investigator;
  • Must be negative for autoimmune disorders in the past 3 months and at Screening - participant's medical history will be used for this evaluation;
  • Must not use any immunosuppressant calcineurin inhibitor product other than SR Injectable tacrolimus throughout the dosing period and until after the final visit;
  • Must agree to blood draws throughout the course of the study and venous access sufficient to allow for blood sampling as per the protocol;
  • Must be negative for selected drugs of abuse at Screening and at Check-in (Day -1);
  • Must have a negative hepatitis panel (including hepatitis B surface antigen [HBsAg] and hepatitis C virus antibody [HCV]) and negative human immunodeficiency virus [HIV] antibody screens;
  • Females will be nonpregnant, nonlactating, and either postmenopausal, defined as amenorrhea for at least 1 year and follicle-stimulating hormone levels of 40 mIU/mL or higher; surgically sterile (eg, tubal ligation, hysterectomy, oophorectomy) for at least 90 days prior to Screening; or agree to use, from the time of signing the informed consent or 10 days prior to Check-in on Day -1 of the Inpatient Period until 30 days after Study Discharge, one of the following forms of contraception: nonhormonal intrauterine device (IUD) with spermicide; female condom with spermicide; contraceptive sponge with spermicide; diaphragm with spermicide; cervical cap with spermicide; male sexual partner who agrees to use a male condom with spermicide; or sterile sexual partner; alternatively, women must agree to maintain abstinence (must agree to use a double barrier method if they become sexually active during the study. For all females of childbearing potential, the pregnancy test result must be negative at Screening and Check-in on Day -1 of the Inpatient Period (see Appendix 1). Women must also agree not to douche throughout the dosing period and until after the final visit;
  • Males will either be sterile or agree to use, from Check-in on Day -1 of the Inpatient Period until 90 days following Study Discharge, one of the following approved methods of contraception: male condom with spermicide; sterile sexual partner; or use by female sexual partner of an IUD with spermicide; a female condom with spermicide; a contraceptive sponge with spermicide; an intravaginal system (eg, NuvaRing®); a diaphragm with spermicide; a cervical cap with spermicide; or oral, implantable, transdermal, or injectable contraceptives. Subjects will refrain from sperm donation from Check-in on Day -1 of the Inpatient Period until 90 days following Study Discharge.

Exclusion Criteria:

  • Inability or unwillingness of a participant to give written informed consent or comply with study protocol;
  • Prisoners or patients who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (eg, infectious disease) illness must not be enrolled into this trial;
  • Presence of an uncontrolled, unstable clinically significant medical condition that in the opinion of the Investigator may increase the risk to the subject or may interfere with the interpretation of safety and PK evaluations, or could impair the subject's ability to complete the trial, or could impair the decisional capacity of the subject;
  • Presence of clinically significant vital signs or a physical examination finding that, in the opinion of the Investigator, could increase the risk to the subject or may potentially interfere with the ability to evaluate safety and tolerability in the trial;
  • History of tacrolimus use, or hypersensitivity and/or adverse reaction to calcineurin inhibitor drugs;
  • History of toxic shock syndrome;
  • Currently receiving chemotherapy or immunosuppressive agents;
  • Use of investigative drugs within 30 days or 5 half-lives of study participation;
  • Currently using sirolimus;
  • Currently using live vaccines;
  • Currently on concomitant substrates and/or inhibitors of CYP3A4;
  • Requires the use of any concomitant medication, except for treatment of an adverse event (AE) during the study;
  • Any abnormality on clinical laboratory tests, or ECG finding that is considered to be clinically significant by the Investigator.
  • Known or suspected (nonfebrile) seizure disorder;
  • Use of any other depot medications within the last three months.
  • Unwilling to commit to avoid eating grapefruit or drinking grapefruit juice during the first 30 days of this exploratory study.
  • Grade ≥ 1 finding as described in the Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03626714


Locations
Layout table for location information
United States, Texas
Worldwide Clinical Trials
San Antonio, Texas, United States, 78217
Sponsors and Collaborators
Auritec Pharmaceuticals
National Institute of Allergy and Infectious Diseases (NIAID)
Investigators
Layout table for investigator information
Principal Investigator: George J Atiee, MD Worldwide Clinical Trials
  Study Documents (Full-Text)

Documents provided by Auritec Pharmaceuticals:

Layout table for additonal information
Responsible Party: Auritec Pharmaceuticals
ClinicalTrials.gov Identifier: NCT03626714     History of Changes
Other Study ID Numbers: RTB-010
U44AI069674 ( U.S. NIH Grant/Contract )
First Posted: August 13, 2018    Key Record Dates
Results First Posted: June 11, 2019
Last Update Posted: August 13, 2019
Last Verified: July 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Auritec Pharmaceuticals:
Tacrolimus
Immunosuppressant
Sustained-release
Plexis
Additional relevant MeSH terms:
Layout table for MeSH terms
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases
Tacrolimus
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Calcineurin Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action